最新临床试验：本妥昔单抗和纳武单抗联合或不联合伊普利单抗治疗复发或难治性霍奇金淋巴瘤

这是经美国国家癌症研究所批准的一项I/II期多中心临床试验，目的是研究伊普利单抗和本妥昔单抗与纳武单抗配伍时的副作用和最佳剂量，以及它们在经过一段时间治疗改善后复发或对以前的治疗没有反应的霍奇金淋巴瘤患者方面的作用。单克隆抗体的免疫治疗，如伊普利单抗和纳武单抗，可能有助于机体的免疫系统攻击癌症，并可能干扰癌细胞的生长和扩散能力。本妥昔单抗是一种结合单克隆抗体和一种抗癌药物，结合淋巴瘤细胞表面一种叫做分化簇（CD）30的蛋白质，可能杀死细胞。目前尚不清楚服用或不服用伊普利单抗的本妥昔单抗和纳武单抗是否能杀死更多的癌细胞。

该临床试验在全美272家医院进行开展。

This phase I / II trial studies the side effects and best dose of ipilimumab and nivolumab when given together with brentuximab vedotin, and how well they work in treating patients with Hodgkin lymphoma that has returned after a period of improvement or has not responded to previous treatment. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Brentuximab vedotin is a combining monoclonal antibody with an anticancer drug that binds to a protein on the surface of lymphoma cells called cluster of differentiation (CD)30 and may kill the cells. It is not known whether giving brentuximab vedotin and nivolumab with or without ipilimumab may kill more cancer cells.

Trial IDs